Skip to content
Clinical Trials – home

Stichting Viecuri Medisch Centrum voor Noord-Limburg

Research site

The Netherlands Tegelseweg 210, 5912 BL Venlo, The Netherlands

  • 27 trials recruiting
  • Arteriosclerosis · Hormone receptor positive HER2 negative breast cancer · Acute coronary syndrome
  • Adult patients

About Specializations

Stichting Viecuri Medisch Centrum voor Noord-Limburg in Venlo, The Netherlands specialises in clinical trials of conditions such as Arteriosclerosis, Hormone receptor positive HER2 negative breast cancer, Acute coronary syndrome, Cardiac failure, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Emergency Care

The research at Stichting Viecuri Medisch Centrum voor Noord-Limburg includes a strong focus on cardiovascular diseases, especially acute and chronic heart conditions seen in emergency settings. Studies address acute coronary syndrome, myocardial infarction, atrial fibrillation, heart failure, and stroke, with the goal of improving prevention, early treatment, and outcomes for high-risk patients.

  • Testing new approaches to reduce major cardiovascular events and death
  • Evaluating better antithrombotic and lipid-lowering strategies
  • Improving care for acute heart attack, stroke, and heart failure patients

This work reflects a broad effort to make emergency and long-term cardiovascular care safer and more effective.

Oncology and Hematologic Malignancies

The site is also active in cancer research, covering both solid tumors and blood cancers. Trials involve breast cancer, colorectal cancer, prostate cancer, lung cancer, esophagogastric cancer, multiple myeloma, and lymphoma, with a focus on testing new treatment combinations, refining therapy selection, and improving survival.

  • Studying targeted and immune-based cancer treatments
  • Assessing treatment effectiveness in advanced and metastatic disease
  • Exploring ways to personalize care using tumor features and biomarkers

These studies show a broad commitment to advancing oncology and hematology research for patients with difficult-to-treat disease.

Metabolic, Endocrine, and Kidney Disease

Clinical trials at this hospital also cover nutritional and metabolic diseases and hormonal disorders, with close links to kidney disease and cardiometabolic risk. Research includes type 2 diabetes, obesity, overweight, hypothyroidism, and chronic kidney conditions, aiming to improve long-term disease control and reduce complications.

  • Testing new therapies for obesity-related cardiovascular and kidney outcomes
  • Evaluating treatments for thyroid disease and persistent symptoms
  • Studying kidney-protective strategies in patients with advanced renal disease

The research portfolio highlights a growing interest in metabolic and endocrine medicine that supports both prevention and chronic disease management.

Immune, Musculoskeletal, and Skin Diseases

Another important area of research focuses on immune system diseases, musculoskeletal disorders, and skin conditions. Trials include psoriatic arthritis, pulmonary sarcoidosis, gout flares, and actinic keratosis, with the aim of improving symptom control, treatment selection, and patient quality of life.

  • Comparing therapies for inflammatory joint and lung disease
  • Testing new options for acute gout symptom relief
  • Studying treatments that may better manage precancerous skin lesions

These studies broaden the site’s work beyond acute care, supporting research in inflammation, dermatology, and rheumatology.

Nervous System and Mental Health

The site is contributing to research in nervous system diseases and psychiatry, including studies in status epilepticus, ischemic stroke, transient ischemic attack, and posttraumatic stress disorder. These trials are designed to improve recovery, reduce long-term disability, and better support patients after serious medical events or trauma.

  • Evaluating treatments that may improve outcomes after cardiac arrest and seizure activity
  • Studying preventive care after stroke and transient ischemic attack
  • Testing early treatment approaches for trauma-related psychological symptoms

This area reflects a practical focus on neurology and mental health in settings where rapid intervention can make a major difference.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Tegelseweg 2105912 BL VenloThe Netherlands
Recruiting now
27 trials
Conditions studied
60

More sites in VenloThe Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

62 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure+1

Recruiting

Study on CDR132L for Heart Failure with Reduced Ejection Fraction and Left Ventricular Hypertrophy in Adults

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.